Plasma concentrations of remoxipride and haloperidol in relation to prolactin and short-term therapeutic outcome in schizophrenic patients

Lahdelma, Riitta-Liisa; Appelberg, Björn; Kuoppasalmi, Kimmo; Katila, Heikki; Rimón, Ranan

doi:10.1016/0924-977x(91)90007-h

Cited by 4 publications

(1 citation statement)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effect of ziprasidone on plasma prolactin concentration in women observed in this study may differ slightly from the effect observed in men, in whom ziprasidone has been associated with only marginal, transient elevations that return to baseline within the dosing interval [15]. This is to be expected, as elevations in plasma prolactin concentrations in women receiving conventional antipsychotic drugs are greater than in men [16–18]. This effect may be attributable to hormonal influences such as oestrogen‐mediated enhancement of prolactin releasing stimuli and the number of lactotrophic cells of the anterior pituitary [18].…”

Section: Discussionmentioning

confidence: 73%

Ziprasidone and the pharmacokinetics of a combined oral contraceptive

Muirhead

Harness

Holt

et al. 2000

Brit J Clinical Pharma

View full text Add to dashboard Cite

Aims To determine whether multiple doses of ziprasidone alter the steady-state pharmacokinetics of the component steroids, ethinyloestradiol and levonorgestrel, of an oral contraceptive; to evaluate the tolerability of a co-administered combined oral contraceptive and ziprasidone; and to compare plasma concentrations of prolactin in subjects taking a combined oral contraceptive with placebo or ziprasidone. Methods Nineteen women taking a combined oral contraceptive (ethinyloestradiol 30 mg day x 1 and levonorgestrel 150 mg day x 1 ) were enrolled into a double-blind, placebo-controlled, two-way crossover study. They received ziprasidone 40 mg day x 1 in two divided daily doses or placebo for 8 days (days 8±15) in one of two 21 day treatment periods separated by a 7 day washout period. Venous blood samples were collected immediately before and up to 24 h after the morning dose of oral contraceptive and ziprasidone or placebo on day 15 of each 21 day treatment period. These were assayed for ethinyloestradiol and levonorgestrel and the resulting data used to derive pharmacokinetic data for these steroids. Additional samples were collected immediately before and 4 h after the morning dose of oral contraceptive and ziprasidone or placebo on day 15 of each 21 day treatment period for prolactin assay. All observed and volunteered adverse events were recorded throughout the study. Results The mean AUC(0,24 h), C max and t max for ethinyloestradiol and the mean AUC(0,24 h) and C max for levonorgestrel during ziprasidone co-administration were not statistically signi®cantly different from corresponding values occurring during placebo co-administration. The t max for levonorgestrel was approximately 0.5 h longer. Concomitant therapy with a combined oral contraceptive and ziprasidone did not result in adverse events not previously seen with either preparation alone. Conclusions The ®ndings of this study suggest that, based on pharmacokinetic and tolerability data, ziprasidone may be co-administered with ethinyloestradiol and levonorgestrel without loss of contraceptive ef®cacy or increased risk of adverse events.

show abstract

Section: Discussionmentioning

confidence: 73%

Ziprasidone and the pharmacokinetics of a combined oral contraceptive

Muirhead

Harness

Holt

et al. 2000

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

Biological Predictors of Antipsychotic Treatment Response

Koreen¹,

Sheitman²,

Lieberman³

1996

Antipsychotics

View full text Add to dashboard Cite

Subhypnotic Doses of Propofol Do Not Possess Antidopaminergic Properties

Borgeat

1997

Anesthesia & Analgesia

View full text Add to dashboard Cite

In order to investigate the possible interactions of propofol with the dopaminergic system, a prospective, randomized, double-blind, placebo-controlled study was performed on the profile of prolactin secretion, since prolactin blood levels are known to increase when dopaminergic receptors are blocked. Ten fasting female patients scheduled to receive cancer chemotherapy were allocated to receive either propofol at a rate of 1 mg.kg-1.h-1 or Intralipid 0.1 ml.kg-1.h-1. The study included two consecutive chemotherapy cycles; each patient received in a random order propofol or Intralipid. The infusions were started 4 h prior to induction of chemotherapy; prolactin blood levels were determined at time 0, 30, 60, 120, and 240 min (end of the study period). The basal prolactin blood levels were 14.2 +/- 4.3 vs 12.8 +/- 2.7 and 10.7 +/- 1.7 vs 14.0 +/- 3.6 ng/mL at the end of the study for propofol and Intralipid, respectively. These results suggest that the antiemetic properties of propofol are not mediated via interactions with the dopaminergic system.

show abstract

Plasma concentrations of remoxipride and haloperidol in relation to prolactin and short-term therapeutic outcome in schizophrenic patients

Cited by 4 publications

References 41 publications

Ziprasidone and the pharmacokinetics of a combined oral contraceptive

Ziprasidone and the pharmacokinetics of a combined oral contraceptive

Biological Predictors of Antipsychotic Treatment Response

Subhypnotic Doses of Propofol Do Not Possess Antidopaminergic Properties

Contact Info

Product

Resources

About